NYSE · PFE
Pfizer Inc.
Healthcare · Drug Manufacturers - General
$30.52▲ 1.90% ($0.57)at close
After hours$30.45▼ 0.22%7:55 PM ET
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price holds with revenue shrinking 5.4% a year for 10 years. Our scenarios assume 0.6–4.4%.
Its past 4 years averaged −6.3% a year.
Value per share
Base case
$57.59
Price used $30.52 is 47% below this
USD · TTM ending Jun 28, 2026 · Price Oct 30, 8:00 PM UTC
Revenue each value needs
Revenue today $63.7B. The price needs $36.4B by 2036. Base case: $69B. At its recent pace: $33.1B. Bear to Bull: $67.6B to $97.9B.
Revenue today $63.7B. The price needs $36.4B by 2036. Base case: $69B. At its recent pace: $33.1B. Bear to Bull: $67.6B to $97.9B.
Revenue in 2036
today $63.7B
−$32.5Bless than the Base case
Value per share · Base case
$57.59
Price $30.52
47% below this
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 26.7%
- Discount rate
- 6.1%
USD · TTM ending Jun 28, 2026 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 25.65% over the last year. Revenue declined 0.22% over the trailing twelve months. Operating margin moved from 26.08% to 26.72%. Free cash flow declined 11.67% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 26.72%. A decisive move in revenue — currently down 0.22% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide.
Market multiples
Stock splits
Every 500 shares became 527
Every 1 shares became 3
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
16
Buy
23
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 3, 2026
Q3 FY26 · EPS est $0.73 · Revenue est $15.9B
Same quarter, year over year
FY26 YTD -10.6%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $1.52 vs $1.70 · 0 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $3.23
- +3.9%
- FY24
- $3.11
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q2 FY26
Reported Aug 4, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.77
Estimate
$0.68
Year over year
-1.3%
Vs prior quarter
+2.7%
Institutional Sentiment
Pfizer Inc. · PFE
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.